Colonoscopy remains the reference standard for colorectal cancer detection, but uptake is constrained by invasiveness, bowel preparation burden, and persistent non-adherence across screening-eligible populations. Liquid biopsy using circulating tumour DNA offers a blood-based alternative, and the 2026 literature positions ctDNA alongside a broader panel of molecular biomarkers as a viable adjunct for early detection, risk stratification, and treatment monitoring, though clinical integration continues to trail the evidence base.
Clinical Key Takeaways
- The Pivot ctDNA and miRNA-based liquid biopsy are now framed in peer-reviewed literature as practical complements to colonoscopy and faecal testing, not merely experimental tools, across detection, risk assessment, and treatment response monitoring in CRC.
- The Data The reviewed literature does not report trial-level HR or p-values; claims of improved sensitivity and patient adherence over conventional screening are qualitative across all three source reviews, which limits quantitative benchmarking at this stage.
- The Action Clinicians should not substitute ctDNA testing for colonoscopy in symptomatic patients today; the current evidence supports awareness of liquid biopsy as an emerging monitoring adjunct while awaiting prospective trial data with hard endpoints.
Colorectal cancer accounts for substantial cancer-related morbidity and mortality worldwide, and the limitations of existing screening infrastructure are well documented. Colonoscopy, while effective, carries procedural risk and generates significant patient reluctance. Faecal-based tests improve access but trade sensitivity for convenience. The gap between what screening programmes need and what current tools deliver has driven sustained research interest in molecular biomarkers that can operate from a peripheral blood sample.1
Three reviews published in 2026 converge on the same core argument: advances in molecular biology and omics technologies have produced a portfolio of candidate biomarkers, with ctDNA and microRNAs representing the most clinically proximate options within the liquid biopsy category.1,2,3 Beyond these, the reviewed literature covers genomic, epigenomic, gut microbiome, metabolomic, and proteomic markers, each proposed as contributors to early detection and personalised treatment frameworks.1,2 The hepatocellular carcinoma literature adds a separate but instructive dimension: ctDNA and circulating free DNA are under evaluation in liver transplantation settings for HCC, where the evidence is described as rising but clinical integration is explicitly characterised as lagging.3
What the reviews cover
All three papers frame liquid biopsy within the broader precision oncology context rather than as a standalone technology.1,2,3 The CRC-focused reviews position ctDNA as useful across three clinical moments: early detection in screening-eligible individuals, risk assessment in those with predisposing conditions, and monitoring of treatment efficacy in patients already diagnosed.1,2 The OMICS review in Molecular Cancer situates these tools within gastrointestinal tumour biology more broadly, emphasising the translational pipeline from bench identification to clinical application.2 The Journal of Gastrointestinal Surgery paper takes a more cautionary register, its title signalling directly that evidence accumulation has outpaced integration into clinical workflows, a tension it examines through the HCC transplant context.3
A critical limitation runs across all three sources: none provides original trial data, patient-level outcomes, or quantitative performance metrics such as sensitivity, specificity, area under the curve, hazard ratios, or p-values for ctDNA assays.1,2,3 The abstracts are qualitative throughout, describing biomarker-based approaches as having "transformative potential" and offering "effective solutions" without anchoring these claims to numbered endpoints.1,2,3 Additionally, two of the three abstracts are textually identical despite appearing under different author groups, journal titles, and stated subject matter, which raises questions about the integrity of the publication record that clinicians relying on this literature should register.1,2 The evidence base for ctDNA in routine CRC practice cannot be quantitatively characterised from these sources alone.
The most striking consequence of reading these three papers together is not what they say about ctDNA but what they cannot say. None provides a sensitivity figure, a false-positive rate, or a survival outcome tied to liquid biopsy use. That is not a minor caveat. It means that any GP or gastroenterologist who hears that ctDNA is ready for integration into CRC screening or monitoring should ask, compared to what, at what threshold, and validated in which population. The answer, from this literature, is unavailable. The potential is real; the numbers are not yet on the table in these reviews.
For the diagnostics industry, the commercial pressure to position liquid biopsy products ahead of the clinical evidence is familiar and well-funded. Companies including Guardant Health and Foundation Medicine have built substantial market positions on ctDNA-based assays, and regulatory clearances have followed in specific indications. What the 2026 review literature reflects is a research community that is catching up with marketing, not leading it. The duplication of abstract text across two nominally distinct papers in this batch also raises a practical concern: if systematic reviewers and meta-analysts downstream incorporate these as independent sources, any quantitative pooling will be inflated. Editors at Clinical Chimica Acta and Molecular Cancer have a problem to address.
Patients eligible for CRC screening deserve clarity on what liquid biopsy can and cannot replace. A blood test that avoids bowel preparation is an obvious appeal, and adherence data from colonoscopy programmes consistently show that a non-invasive alternative would reach people the current system does not. But deploying ctDNA testing without validated sensitivity and specificity data in a screening context risks both false reassurance and unnecessary downstream investigation. The integration gap that Shoucair and colleagues name explicitly in the HCC transplant context applies equally here: the bottleneck is not enthusiasm or even emerging evidence. It is the absence of prospective, outcome-linked trial data rigorous enough to anchor a guideline recommendation. Until NICE, the USPSTF, or equivalent bodies have that data in front of them, ctDNA in CRC remains a watch-and-wait technology for clinical practice, whatever the review literature implies.
How to cite this article
Team E. Ctdna liquid biopsy in colorectal cancer: where the evidence sits now. The Life Science Feed. Accessed April 26, 2026. https://thelifesciencefeed.com/oncology/colorectal-neoplasms/ctdna-liquid-biopsy-colorectal-cancer-evidence-2026.
Copyright and license
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Fact-Checking & AI Transparency
This article was researched and drafted with AI assistance, then reviewed and approved for publication by the Editor. All content is sourced from peer-reviewed, open-access research. It does not represent the views of any pharmaceutical company or healthcare provider.
Our AI tools are used to summarise and structure published research only. Every article is checked by a human editor before going live — no article is published without editorial review.